AGC expanding CDMO biz through $500m CMC Biologics buy

By Dan Stanton

- Last updated on GMT


Related tags Cmc biologics Biotechnology Chemistry Chemical industry

AGC Asahi Glass has signed an agreement to buy CMC Biologics, the second biologics CDMO acquisition for the Japanese chemicals firm in three months.

The firm said it is paying around  ¥60bn ($509m) for the contract development and manufacturing organization (CDMO), adding 530 employees and production facilities in Copenhagen, Denmark and US sites in Seattle and Berkeley.

CMC Biologics Chairman David Kauffmann said he was “excited” by becoming part of AGC.

“AGC's dedication to best technology solutions and long-time partnership with clients align so well with CMC Biologics' quest to be the preferred biologics CDMO service partner for the world's top pharmaceutical and biotech companies.”

CMC announced earlier this year​ it had invested in three Thermo Fisher 2,000L single-use bioreactors to be installed at its Copenhagen plant, offering customers 6,000L of volume in a single run through its 6PACK configuration platform.

The acquisition comes three months after AGC bought German CDMO Biomeva​.

The deal was described as a leap into the microbial biologics contract manufacturing space for the Japanese chemical and glassmaker, adding 1,500L of capacity at Biomeva’s facility in Heidelberg.

AGC did not respond to a request for further information at the time of going to press regarding the latest acquisition.

Related news

Show more

Related products

show more

eBook: mRNA prospects and scale-up solutions

eBook: mRNA prospects and scale-up solutions

Thermo Fisher Scientific - Biosciences | 22-Mar-2023 | Insight Guide

This mRNA eBook was created by Thermo Fisher Scientific, in collaboration with Genetic Engineering & Biotechnology News (GEN), to provide you with...

Create Better Biologic Treatments with Catalent

Create Better Biologic Treatments with Catalent

Catalent | 21-Feb-2023 | Product Brochure

Deliver safe and stable products to your patients with the help of Catalent Biologics' Limoges, France site, a European Center of Excellence for early-phase...

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

Related suppliers

Follow us


View more